Section Arrow
DNTH.NASDAQ
- Dianthus Therapeutics
Quotes are at least 15-min delayed:2026/07/09 21:31 EDT
Regular Hours
Last
 100.03
+1.96 (+2.00%)
Day High 
102.33 
Prev. Close
98.07 
1-M High
98.7 
Volume 
2.40M 
Bid
90
Ask
104
Day Low
98.3 
Open
98.78 
1-M Low
68.8483 
Market Cap 
5.36B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 94.26 
20-SMA 88.14 
50-SMA 87.17 
52-W High 98.7 
52-W Low 18.08 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.23/-5.49
Enterprise Value
5.36B
Balance Sheet
Book Value Per Share
21.98
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.04M
Operating Revenue Per Share
0.12
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VRAXVirax Biolabs Group Limited6.36+3.18+100.00%-- 
EVGNEvogene Ltd.0.5+0.0859+20.74%-- 
RXRXRecursion Pharmaceuticals3.76+0.04+1.08%-- 
IONSIonis Pharmaceuticals64.27-20.19-23.90%-- 
BBIOBridgeBio Pharma90.17+11.84+15.12%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.